naftopidil has been researched along with Urination Disorders in 20 studies
Urination Disorders: Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the efficacy of dose increase therapy in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia who responded poorly to 50 mg/day of naftopidil." | 9.17 | α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy. ( Kakizaki, H; Numata, A; Osanai, H; Watanabe, M; Yamaguchi, S, 2013) |
| "We compared the efficacy, safety, and patient preferences for two α1-adrenoceptor (AR) antagonists with different affinity for AR subtypes, naftopidil (Naf) and silodosin (Silo), for the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (male LUTS/BPH)." | 9.16 | [Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study]. ( Asakura, T; Hashiba, T; Jinza, S; Masuda, M; Masuko, H, 2012) |
| "To investigate the incidence of ejaculatory disorders caused by naftopidil and tamsulosin in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)." | 9.14 | Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. ( Furuya, R; Iwasawa, A; Masumori, N; Mori, M; Sonoda, T; Tsukamoto, T, 2009) |
| "We examined the tolerability of dosage methods of naftopidil in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH/male LUTS)." | 9.14 | A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily. ( Kazama, T; Kimura, H; Nozaki, T; Okumura, A; Tsuritani, S, 2010) |
| "To compare the efficacy of two alpha(1)-adrenoceptor antagonists, alpha(1A)-adrenoceptor-selective tamsulosin hydrochloride and alpha(1D)-adrenoceptor-selective naftopidil, in the treatment of lower urinary tract symptoms (LUTS) with benign prostatic hyperplasia (BPH)." | 9.12 | Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. ( Deguchi, T; Ishihara, S; Masue, T; Miwa, K; Nishino, Y; Takahashi, Y, 2006) |
| "The present study investigated the efficacy, safety, and utility of starting an alpha(1d)-selective antagonist, naftopidil, at 75 or 25 mg/day in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)." | 9.12 | Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study. ( Kumon, H; Nasu, Y; Takamoto, H; Watanabe, T; Yokoyama, T, 2006) |
| "We studied the efficacy of naftopidil (50 mg/day) on nocturia associated with benign prostatic hyperplasia in 35 patients (62-80 years old)." | 9.10 | [Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia]. ( Araki, I; Fukuzawa, S; Hashimura, T; Soeda, T; Sugino, Y; Takeuchi, H; Taki, Y, 2003) |
| "Naftopidil, a phenylpiperazine derivative, is a novel alpha 1-adrenoceptor antagonist and is new drug for the bladder outlet obstruction in patients with benign prostatic hyperplasia (BPH)." | 8.80 | [Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia]. ( Ikegaki, I, 2000) |
| "We examined the effectiveness of naftopidil in 81 patients with lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH)." | 7.74 | [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index]. ( Hamano, S; Murakami, S; Nakatsu, H; Naoi, M; Sekiyama, K; Suzuki, N; Tanaka, M, 2007) |
| "Naftopidil was administered to 67 patients with benign prostatic hyperplasia (BPH) for 12 months." | 7.72 | [Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia]. ( Akasaka, T; Fujishima, M; Funaki, H; Hirano, S; Iinuma, M; Kudou, T; Ohinata, M; Suzuki, A, 2003) |
| "Tamsulosin was more effective than naftopidil on intermittency, nocturia and quality of life scores." | 6.73 | Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. ( Hosokawa, Y; Kishino, T; Momose, H; Ono, T; Oyama, N, 2007) |
| "Naftopidil was administered for three months to the patients with BPH who had nocturia with a urinary frequency of two or more times." | 5.32 | [Etiology of nocturia and clinical efficacy of naftopidil on nocturia in patients with benign prostatic hyperplasia--analysis of frequency volume charts]. ( Furuhata, A; Hirokawa, M; Hiromoto, Y; Ikeda, A; Kawasaki, C; Masuda, M; Nakayama, K; Satomi, Y; Shiramizu, M, 2004) |
| "To examine the efficacy of dose increase therapy in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia who responded poorly to 50 mg/day of naftopidil." | 5.17 | α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy. ( Kakizaki, H; Numata, A; Osanai, H; Watanabe, M; Yamaguchi, S, 2013) |
| "We compared the efficacy, safety, and patient preferences for two α1-adrenoceptor (AR) antagonists with different affinity for AR subtypes, naftopidil (Naf) and silodosin (Silo), for the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (male LUTS/BPH)." | 5.16 | [Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study]. ( Asakura, T; Hashiba, T; Jinza, S; Masuda, M; Masuko, H, 2012) |
| "To investigate the incidence of ejaculatory disorders caused by naftopidil and tamsulosin in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)." | 5.14 | Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. ( Furuya, R; Iwasawa, A; Masumori, N; Mori, M; Sonoda, T; Tsukamoto, T, 2009) |
| "We examined the tolerability of dosage methods of naftopidil in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH/male LUTS)." | 5.14 | A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily. ( Kazama, T; Kimura, H; Nozaki, T; Okumura, A; Tsuritani, S, 2010) |
| "To compare the efficacy of two alpha(1)-adrenoceptor antagonists, alpha(1A)-adrenoceptor-selective tamsulosin hydrochloride and alpha(1D)-adrenoceptor-selective naftopidil, in the treatment of lower urinary tract symptoms (LUTS) with benign prostatic hyperplasia (BPH)." | 5.12 | Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. ( Deguchi, T; Ishihara, S; Masue, T; Miwa, K; Nishino, Y; Takahashi, Y, 2006) |
| "The present study investigated the efficacy, safety, and utility of starting an alpha(1d)-selective antagonist, naftopidil, at 75 or 25 mg/day in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)." | 5.12 | Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study. ( Kumon, H; Nasu, Y; Takamoto, H; Watanabe, T; Yokoyama, T, 2006) |
| "We studied the efficacy of naftopidil (50 mg/day) on nocturia associated with benign prostatic hyperplasia in 35 patients (62-80 years old)." | 5.10 | [Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia]. ( Araki, I; Fukuzawa, S; Hashimura, T; Soeda, T; Sugino, Y; Takeuchi, H; Taki, Y, 2003) |
| "Naftopidil, a phenylpiperazine derivative, is a novel alpha 1-adrenoceptor antagonist and is new drug for the bladder outlet obstruction in patients with benign prostatic hyperplasia (BPH)." | 4.80 | [Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia]. ( Ikegaki, I, 2000) |
| "We examined the effectiveness of naftopidil in 81 patients with lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH)." | 3.74 | [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index]. ( Hamano, S; Murakami, S; Nakatsu, H; Naoi, M; Sekiyama, K; Suzuki, N; Tanaka, M, 2007) |
| "Naftopidil was administered to 67 patients with benign prostatic hyperplasia (BPH) for 12 months." | 3.72 | [Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia]. ( Akasaka, T; Fujishima, M; Funaki, H; Hirano, S; Iinuma, M; Kudou, T; Ohinata, M; Suzuki, A, 2003) |
| "Tamsulosin was more effective than naftopidil on intermittency, nocturia and quality of life scores." | 2.73 | Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. ( Hosokawa, Y; Kishino, T; Momose, H; Ono, T; Oyama, N, 2007) |
| "Naftopidil was administered for three months to the patients with BPH who had nocturia with a urinary frequency of two or more times." | 1.32 | [Etiology of nocturia and clinical efficacy of naftopidil on nocturia in patients with benign prostatic hyperplasia--analysis of frequency volume charts]. ( Furuhata, A; Hirokawa, M; Hiromoto, Y; Ikeda, A; Kawasaki, C; Masuda, M; Nakayama, K; Satomi, Y; Shiramizu, M, 2004) |
| " KT-611 at a dosage of once or twice a day was evaluated for its effects on 49 patients with benign prostatic hypertrophy." | 1.28 | [Effect of KT-611 (Naftopidil) on the contraction of human prostatic tissue and its use in benign prostatic obstruction]. ( Fukaya, Y; Itou, K; Kameoka, H; Kuma, Y; Kumakawa, K; Shiraiwa, Y; Yamaguchi, O; Yamanaka, N; Yokota, T; Yokoyama, J, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 12 (60.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ukimura, O | 1 |
| Kanazawa, M | 1 |
| Fujihara, A | 1 |
| Kamoi, K | 1 |
| Okihara, K | 1 |
| Miki, T | 1 |
| Ishizaka, K | 1 |
| Machida, T | 1 |
| Tanaka, M | 2 |
| Kawamura, N | 1 |
| Nakamura, K | 1 |
| Kihara, K | 1 |
| Masumori, N | 1 |
| Tsukamoto, T | 1 |
| Iwasawa, A | 1 |
| Furuya, R | 1 |
| Sonoda, T | 1 |
| Mori, M | 1 |
| Tsuritani, S | 1 |
| Nozaki, T | 1 |
| Okumura, A | 1 |
| Kimura, H | 1 |
| Kazama, T | 1 |
| Yokoyama, T | 2 |
| Hara, R | 1 |
| Fukumoto, K | 1 |
| Fujii, T | 1 |
| Jo, Y | 1 |
| Miyaji, Y | 1 |
| Nagai, A | 1 |
| Sone, A | 1 |
| Yamaguchi, S | 1 |
| Osanai, H | 1 |
| Numata, A | 1 |
| Watanabe, M | 1 |
| Kakizaki, H | 1 |
| Park, WH | 1 |
| Ishizuka, O | 1 |
| Funahashi, Y | 1 |
| Masuda, M | 2 |
| Jinza, S | 1 |
| Masuko, H | 1 |
| Asakura, T | 1 |
| Hashiba, T | 1 |
| Akasaka, T | 1 |
| Funaki, H | 1 |
| Hirano, S | 1 |
| Ohinata, M | 1 |
| Fujishima, M | 1 |
| Kudou, T | 1 |
| Suzuki, A | 1 |
| Iinuma, M | 1 |
| Sugino, Y | 1 |
| Fukuzawa, S | 1 |
| Takeuchi, H | 1 |
| Taki, Y | 1 |
| Hashimura, T | 1 |
| Soeda, T | 1 |
| Araki, I | 1 |
| Ikemoto, I | 1 |
| Kiyota, H | 1 |
| Ohishi, Y | 1 |
| Abe, K | 1 |
| Goto, H | 1 |
| Kishimoto, K | 1 |
| Miki, K | 1 |
| Nakayama, K | 1 |
| Hiromoto, Y | 1 |
| Hirokawa, M | 1 |
| Satomi, Y | 1 |
| Shiramizu, M | 1 |
| Furuhata, A | 1 |
| Ikeda, A | 1 |
| Kawasaki, C | 1 |
| Nishino, Y | 1 |
| Masue, T | 1 |
| Miwa, K | 1 |
| Takahashi, Y | 1 |
| Ishihara, S | 1 |
| Deguchi, T | 1 |
| Kumon, H | 1 |
| Nasu, Y | 1 |
| Takamoto, H | 1 |
| Watanabe, T | 1 |
| Nakatsu, H | 1 |
| Naoi, M | 1 |
| Sekiyama, K | 1 |
| Hamano, S | 1 |
| Suzuki, N | 1 |
| Murakami, S | 1 |
| Momose, H | 1 |
| Hosokawa, Y | 1 |
| Kishino, T | 1 |
| Ono, T | 1 |
| Oyama, N | 1 |
| Ikegaki, I | 1 |
| Yamanaka, N | 1 |
| Yamaguchi, O | 1 |
| Kameoka, H | 1 |
| Fukaya, Y | 1 |
| Yokota, T | 1 |
| Shiraiwa, Y | 1 |
| Yokoyama, J | 1 |
| Kumakawa, K | 1 |
| Itou, K | 1 |
| Kuma, Y | 1 |
1 review available for naftopidil and Urination Disorders
| Article | Year |
|---|---|
[Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Animals; Binding, Competitive; Dogs; Humans; Male; Naphthalenes; | 2000 |
11 trials available for naftopidil and Urination Disorders
| Article | Year |
|---|---|
Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Prospectiv | 2008 |
Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
Topics: Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Male; Middle Aged; Naphthalenes; Piperazine | 2009 |
A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Huma | 2010 |
Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Ejaculation; Erectile Dysfunction; | 2011 |
α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Dose-Response Relationship, Drug; Humans; Male; Middl | 2013 |
[Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study].
Topics: Adrenergic alpha-Antagonists; Cross-Over Studies; Humans; Indoles; Male; Naphthalenes; Piperazines; | 2012 |
[Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; M | 2003 |
Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study.
Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Dizziness; Headache; Humans; Hypotension, Or | 2003 |
Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Humans; Male; Naphthalenes; Piperazines; Pro | 2006 |
Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2006 |
Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cross-Over Studies; Drug Therapy, Combination | 2007 |
8 other studies available for naftopidil and Urination Disorders
| Article | Year |
|---|---|
Clinical efficacy of naftopidil on lower urinary tract symptoms after radical prostatectomy.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Admini | 2009 |
Editorial comment from Dr Park to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperpla | 2013 |
Editorial comment from Dr Ishizuka to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperpla | 2013 |
Editorial comment from Dr Funahashi to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Humans; Male; Naphthalenes; Piperazines; Prostatic Hyperpla | 2013 |
[Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; Male; M | 2003 |
[Etiology of nocturia and clinical efficacy of naftopidil on nocturia in patients with benign prostatic hyperplasia--analysis of frequency volume charts].
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Circadian Rhythm; Drug Administration Schedul | 2004 |
[The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
Topics: Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middle Aged; Naphtha | 2007 |
[Effect of KT-611 (Naftopidil) on the contraction of human prostatic tissue and its use in benign prostatic obstruction].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Humans; | 1991 |